Navigation Links
Phase III data show efficacy/safety of iclaprim in patients with complicated skin infections
Date:10/27/2008

patients. In a combined efficacy analysis, the clinical cure rate at the test-of-cure visit was 82.2 percent for iclaprim versus 85.3 percent for linezolid in the intent-to-treat population and cure rates were 92.3 percent and 97.8 percent, respectively, in the per protocol population. Data from the studies also show that iclaprim exhibited a high eradication rate for MRSA (76.4 percent), which was comparable to that of linezolid (78.7 percent).

Overall, iclaprim was found to be safe and well-tolerated at a dose of 0.8 mg/kg in the Phase III ASSIST trials. Adverse events were found to be less frequent among patients treated with iclaprim as compared to linezolid. In earlier Phase I trials, iclaprim was shown to have a low propensity for interactions with other drugs.

"These data further support the safety and efficacy of iclaprim as a potential treatment against complicated skin and skin structure infections," said Jrgen Raths MD, President and CEO of Arpida. "Arpida remains encouraged and optimistic about the potential of iclaprim for the treatment of MRSA and related infections, and looks forward to bringing iclaprim to market, providing a new treatment option for physicians."

The ASSIST Trials

The ASSIST trials were randomized, multi-center, double-blind, Phase III studies designed to establish the efficacy and safety of iclaprim in the treatment of patients with cSSSI known or suspected to be caused by Gram-positive pathogens. The trials were of essentially identical design, making a combined analysis of iclaprim possible in a larger population. A 95 percent confidence interval was used to determine statistical significance of study data and the pre-specified non-inferiority margin (-12.5 percent) was met in all populations in both trials.

A total of 991 patients, 18 years old and over with cSSSIs were enrolled in the trials. Patients were treated for 10 to 14 days with either 0.8 mg/kg iclaprim or 600 mg linezol
'/>"/>

Contact: Dr. Jrgen Raths
41-614-179-660
Zeno Group
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet
2. Improved foam for varicose veins found to be safe in preliminary results from phase II trial
3. Moms obesity during conception phase may set the stage for offsprings obesity risk
4. Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth
5. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
6. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
7. CABI helps phase out dangerous pesticide in EU
8. SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
9. New test promises quicker, more accurate evaluation for cystic fibrosis patients
10. How eating fruit and vegetables can improve cancer patients response to chemotherapy
11. UCSF Fresno leading-edge study lends hope to emphysema patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... its touch fingerprint sensor FPC1025 from the distributor World ... will commence during Q2 2015 although the major part ... The sensors will be used by smartphone manufacturers in ... 110 MSEK is included in the communicated revenue guidance ...
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... Neural stem cells represent the cellular backup of ... form new stem cells or differentiate into neurons, astrocytes ... of neurons, while oligodendrocytes form the myelin layer around ... how does a neural stem cell know" which way ...
... of researchers from the British Antarctic Survey have collected individuals ... waters and subjected them to increasing levels of water temperature ... the conditions that they are likely to experience in the ... already living really close to their upper temperature range, and ...
... of Wisconsin-Madison biomedical engineer and colleagues have developed a method ... some women with increased breast cancer risk the pain and ... lump or lesion. The universal technology will give radiologists ... benign. The American Cancer Society recommends that women ...
Cached Biology News:Neural stem cell differentiation factor discovered 2New MRI technique could mean fewer breast biopsies in high-risk women 2
(Date:4/30/2015)...  The Paul G. Allen Family Foundation announced today ... six groups of researchers with projects at the frontier ... growing mature human brain cells in the laboratory. The ... over three years.  "This new cohort ... significant because the field of neuronal maturation is at ...
(Date:4/30/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that it will release first quarter financial ... the close of the U.S. financial markets. The Company ... May 7, 2015 at 4:30 p.m. Eastern / 1:30 ... developments. For both "listen-only" participants and those ...
(Date:4/30/2015)... -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") ... services provider, today announced that its board of directors ... 29, 2015, from a consortium (the "Consortium") led by ... and chief executive officer of the Company, and Ally ... (the "Transaction") involving the acquisition of all outstanding shares ...
(Date:4/30/2015)... 30, 2015 Available in select ... http://www.lespausa.com , Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield ... skin while battling the weakening threat of inflammaging, ... is formulated with star ingredient GLYCOSEA, a complex ... a complex of soothing minerals and trace elements. ...
Breaking Biology Technology:The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3
... NEW YORK, Nov. 11 Cynvec LLC, a ... that,harness the apoptotic ability of the Sindbis viral ... the Rodman & Renshaw 10th,Annual Healthcare Conference to ... the New York Palace Hotel in New York ...
... SANTA MONICA, Calif., Nov. 11 Cord Blood,America, ... blood stem,cell preservation company ( http://www.cordblood-america.com ) focused ... to families nationwide and,internationally, said today that the ... President-elect Barack Obama intends to use his executive,authority ...
... Graphene is a perfect example of the wonders of nanotechnology, ... level to uncover new and exciting possibilities. ... form of all graphitic carbon, which is used to make ... is reduced down to a one-atom-thick sheet. Graphene is among ...
Cached Biology Technology:Cord Blood America Salutes President-Elect Obama's Promise to Lift Restrictions on Stem Cell Research 2Researchers discover method for mass production of nanomaterial graphene 2Researchers discover method for mass production of nanomaterial graphene 3
... gel systems used gasketed gel trays. Turn the tray ... Turn it back and run the gel - its ... & Cast tray is UV transparent. Each tray accommodates ... tray and one in the center. This allows you ...
... your ValveBank system! Program your valve ... computer using graphic 'click-and-drag' timebars. Save and ... program listings, then download your programs into ... EasyCode is used for programming before -- ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
... The Jouan MSC series of ... comfortable working conditions and certification to ... automatic regulation ensures that the cabinets ... working conditions. Natural lighting, low noise ...
Biology Products: